Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-18650

Russmann, S; Szeless, T; Bock, A; Kullak-Ublick, G A (2009). Natriumphosphat enthaltende Darmreinigungsmittel – eine Gefahr für die Niere? Swiss Medical Forum, 9(18):336-339.

[img]
Preview
Creative Commons: Attribution 3.0 Unported (CC BY 3.0)
PDF (final manuscript)
1MB
[img]
Preview
Published Version
PDF
2MB

Abstract

There are several well-documented cases of acute irreversible renal failure involving renal calcium phosphate deposits after the use of bowel preparations containing sodium phosphate (e.g., Colophos®).
- Neither randomised clinical nor epidemiological studies have established an
association between sodium phosphate use and renal damage in patients without preexisting renal dysfunction.
- However, it is likely that patients with preexisting renal dysfunction and other risk factors were not sufficiently represented and analysed in these studies, and may be at increased risk of (further) renal damage through sodium phosphate.
- Recommendations for clinical practice:
1. Routine determination of renal function through GFR estimation before prescription of bowel cleansing preparations containing sodium phosphate.
2. If sodium phosphate is administered, sufficient hydration is crucial: 2 L of fluids should be consumed with each 90 ml bottle of Colophos®.
3. Sodium phosphate should not be used in patients with preexisting renal dysfunction (GFR <60 ml/min), and in those with other risk factors (heart failure, concomitant use of ACE inhibitors, angiotensin receptor blockers and diuretics, preexisting dehydration and electrolyte disorders, old age). Bowel preparations containing polyethylene glycol (e.g., Cololyt®) should be given to these patients.

Citations

Downloads

395 downloads since deposited on 27 May 2009
57 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:2009
Deposited On:27 May 2009 11:16
Last Modified:06 Jun 2016 12:59
Publisher:EMH Swiss Medical Publishers
ISSN:1424-3784
Free access at:Publisher DOI. An embargo period may apply.
Official URL:http://www.medicalforum.ch/pdf/pdf_d/2009/2009-18/2009-18-018.PDF

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page